BSEOthers4d ago · 3 Aug 2026, 03:12 pm
Submission of the Annual Report for the FY 2025-26, containing Audited Standalone Financial Statements, Auditors Report and Directors Report and the Notice convening 41st Annual General ....
Jenburkt Pharmaceuticals Ltd · 524731
✦ AI SummaryResults
Jenburkt Pharmaceuticals Ltd has submitted its Annual Report for FY 2025-26, including audited standalone financial statements, auditors' report, and directors' report. The report also includes a notice convening the 41st Annual General Meeting to be held on September 4, 2026, and proposes to declare a dividend of ₹ 20.70 per equity share.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Jenburkt Pharmaceuticals Ltd - 524731 - Reg. 34 (1) Annual Report.